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Cigarette smoking is firmly linked to the occurrence of acute coronary events. In twenty-two healthy volun-
teers in normal conditions of daily life we studied the acute influence of smoking on the following parameters:
beta-thromboglobulin, thromboxane B2, epinephrine, norepinephrine, estrogen-stimulated neurophysin, and
nicotine-stimulated-neurophysin. Our results show that in our population and following our protocol,
smoking did not induce platelet activation, thromboxane formation, catecholamine release or estrogen-
stimulated-neurophysin secretion. However, smoking did provoke a significant increase of nicotine-
stimulated-neurophysin (p<0-05) which reflects vasopressin increase and which might explain the high
incidence of ischaemic accidents in cigarette smoking via the vasoactive properties of vasopressin.
Cigarette smoking is a well-recognised risk factor
of coronary artery disease11"31. The mechanisms
whereby smoking contributes to the development
and ischaemic complications of coronary athero-
sclerosis are not well elucidated: smoking-
induced catecholamines release14' and platelet
activation'5"61 have been proposed but without
general agreement'7'. The present work tries to
clarify these two points. In addition, we have
studied the alteration of the two neurophysins.
The neuro-hypophysis of mammals contains
vasopressin (AVP), oxytocin (OT) and their carrier
proteins called neurophysins. There is consider-
able evidence that AVP and OT are released into
the circulation, together with their specific
neurophysin'8"10'. Recently, it was demonstrated
that each hormone and its neurophysin originate
from the same precursor"11. AVP and OT have
vasoactive properties and may play a role in trig-
gering acute coronary events associated with
cigarette smoking, since recent observations sug-
gest that tobacco could act as a transient and rever-
sible factor rather than via the promotion of
atherosclerosis"2" '*'.
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The protocol used was specially designed to
study these different variables when the subjects
•are under normal conditions of daily life, because
smoking-associated coronary events occur usually
in these conditions, and not in an experimental
context.
Methods
POPULATION:
The studied population consisted of 22 healthy
volunteers; 14 were males and 8 females with a
mean age of 30 years (range: 18 to 56). The 22 sub-
jects were regular smokers and were selected for
their capacity to inhale tobacco smoke. Four out
of the 8 females were taking oral contraceptives.
PROTOCOL
All the subjects smoked 2 cigarettes containing
l-2mg of nicotine, at 10 a.m., without previous
rest but after an overnight abstinence from
smoking.
During the whole test, the subjects did not
change their usual daily occupation, desk or
laboratory work. Blood samples were drawn in all
the subjects in the sitting position before smoking
and about 20 min later by two different venipunc-
tures. This time interval between blood samples
was chosen in accordance with the study of
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Levine1*1, in which this interval seemed to be the
best time frame to detect the major change in
platelet substances, and with the results of Cryer151
which showed the highest catecholamine values
between 10 and 20 min after smoking. The second
venipuncture, performed on the opposite arm
10 min after the end of smoking, was preferred to
butterfly sampling to avoid artefactual platelet
activation'1" and to reproduce the possible punc-
ture stress while mimicking normal daily life
activity. In addition, in 5 subjects, blood samples
were drawn at 5 min intervals during half an hour
to study the catecholamine response to smoke as a
function of time. In parallel, the pulse rate and
systolic blood pressure were recorded and the
double product was calculated in these 5 subjects.
No haemodynamic measurements were done in the
rest of the population.
PLATELET STUDY
Platelet function was evaluated by measure-
ments of the two platelet-specific substances, beta-
thromboglobulin (pTG) and thromboxane B2
(TXB2). PTG and TXB2 plasma levels were
measured by radioimmunoassay, with commercial
RIA Kits (respectively, New England Nuclear,
Boston, MA, USA, and Serono Diagnostics,
Switzerland) by methods previously described1131.
RELEASE OF POSTERIOR HYPOPHYSIAL PEPTIDES
This was evaluated by determination of plasma
levels of the two neurophysins. Each neurophysin
is specifically associated with one neurohormone
and has distinct electrophoretic mobilities, im-
munological properties, and responses to different
stimuli. For instance, the vasopressin-associated
neurophysin is released not only in response to
variations in osmolarity but also to nicotine
stimulation; therefore it is named nicotine-
stimulated-neurophysin (NSSN). The oxytocin-
associated-neurophysin is released in response to
estrogen stimulation, and is named estrogen-
stimulated-neurophysin (ESN)1161171. It is widely
accepted that the plasma levels of neurophysins
reflect the plasma levels of the associated neuro-
hormones'8'161. The two neurophysins were
measured by radioimmunoassay using methods
described elsewhere in detail'17-181.
CATECHOLAMINE STUDY
Epinephrine and norepinephrine were deter-
mined according to the method of Da Prada and
Zurcher1191, as modified by Michelet et a/.'201.
STATISTICAL ANALYSIS
Paired t-tests were used to compare resting and
smoking values.
Results
PLATELET STUDY
Plasma TXB2 and /TTG concentrations before
and after smoking are shown in Fig. 1. The mean
(±SD) plasma TXB2 level was 118±40pg per
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Figure 1 Platelet response to tobacco smoke.
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Figure 2 Changes in plasma epinephnne and norepinephnne dunng smoking.
milliliter before smoking, and did not change sig-
nificantly 20 min after the beginning of smoking:
119±41pgml"1. The mean plasma /3TG levels
showed no significant change: 19±5ngml~1
before and 17 ± 4 ng ml"' after smoking.
CATECHOLAMINE STUDY
Figure 2 shows the individual and mean values
(±SD) of plasma concentrations of epinephnne
and norepinephnne before and 20 min after the
beginning of smoking. We found no difference for
epinephrine: 69±30pgml" ' before versus
65±26pgml~' after, whereas we found a slight
but significant decrease of norephinephrine:
S mo kin
288 ±69 pg ml" versus 211±48pgml'
(P <005). However, there was a rather wide varia-
tion in the individual values.
In 5 subjects, blood samples were drawn every
5 min, in addition to non-invasive haemodynamic
determinations.
The mean pulse rate, systolic blood pressure,
double product and plasma epinephrine and nor-
epinephrine concentrations before, during and
after smoking are shown in Fig. 3. Smoking was
associated with large increments of pulse rate,
blood pressure and double product (P< 0-005), but
a significant fall of plasma norepinephrine con-
centration was observed, confirming the previous
measurements. The epinephrine profile did not
show any significant rise compared to the level
prior to smoking; on the contrary, after 25 min,
there was a significant fall of epinephrine.
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Figure 3 Mean heart rate, systolic blood pressure, double
product and plasma catecholamines before, during and after
smoking in five subjects.
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NEUROPHYSINS
Figure 4 indicates the individual values of ESN
before and after smoking. No change occurred:
353±94pgml- ' versus 326± 111 pgml" ' . How-
ever, as expected, the values of the females taking
oral contraceptives were elevated, before and after
smoking, being 2 to 4 times higher than the rest of
the population.
Contrary to the effect on ESN, smoking in-
duced a significant increase of NSN (see Fig.
5): 283±52pgml"1 versus 520 ± 405 pg ml"'
(P<005). This increase did not occur in all the
subjects. If we define 'responders' as subjects who
increase their NSN levels more than 2 SD of the
mean level prior to smoking, we find that only 12
out of the 22 subjects are 'responders'. The NSN
increase was unrelated, in our population, to sex or
to the platelet and catecholamine responses to
smoking. Moreover, of the 5 subjects in whom
haemodynamic measurements were recorded, only
one was a 'NSN responder' during smoking, and
had an haemodynamic profile similar to the other
four.
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Figure 4 Plasma ESN (Estrogen-stimulated-neurophysin)
before and after smoking. (AC pill: anticoncepuonal pill).
Figure 5 Changes of plasma NSN (nicotine-stimulated-
neurophysin) before and after smoking.
Discussion
Our results show that in our population and
during normal daily activity, cigarette smoking did
not induce platelet activation, thromboxane form-
ation, catecholamine rise or ESN secretion. How-
ever, the vasopressin-associated-neurophysin was
significantly increased after smoking. This in-
crease, which reflects AVP increase18161, occurred
only in about half of our subjects, suggesting an
individual susceptibility to cigarette smoke (and
probably to nicotine).
In view of the putative triggering effect of smoke
on acute coronary events, these observations are
very important. It is well known that vasopressin
administered therapeutically for gastrointestinal
bleeding or for diabetes insipidus (even at low
doses) can cause ischaemic accidents and some-
times sudden death in patients with coronary
atherosclerosis'2'1. As suggested by recent publi-
cations, vasopressin could act by promoting
coronary spasm'22' or by elevating coronary
resistance in patients with coronary artery
disease123'24'.
In a previous study'41, smoking-associated
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sympathetic discharge has been proposed as a
mechanism for the adverse effect of smoking in
patients with coronary atherosclerosis. There was
no temporal association between the increase of
pulse rate and blood pressure and the increase of
plasma catecholamines. The authors proposed,
however, that local catecholamine release medi-
ated haemodynamic changes. In our study, despite
a different protocol, smoking-associated increases
in heart rate, blood pressure and subsequent
double product were also found, but were not
associated with an elevation of circulating cate-
cholamines. Moreover, the catecholamine levels
observed in our subjects are similar to those
obtained in several studies of normal subjects in
the sitting position1251. Our study protocol was
designed to maintain the usual conditions of the
smoker in daily life and to avoid any additional
experimental stress but the venipuncture. The
haemodynamic changes cannot be attributed to
the stress of the venipuncture since it began largely
after the venipuncture (see Fig. 3). If these
haemodynamic changes explain the occurrence of
ischaemic accidents in subjects with an already
compromised coronary circulation, via increases in
cardiac work and oxygen consumption, they can-
not be attributed to sympathetic discharge alone
but to a more complicated mechanism. One hypo-
thesis would involve an imbalance of the sympa-
thetic and parasympathetic equilibrium, induced
by nicotine effects at autonomic ganglia; indeed,
the complex and often unpredictable changes that
occur in the body after the parenteral administra-
tion of nicotine are partly due to its stimulant and
depressant phases of action'261. The minimal vari-
ations in norepinephrine and epinephrine levels
measured in individual subjects after smoking sug-
gest that the physical and psychological status of
the smoker may play an important role and may
attenuate the catecholamine changes observed in
other reports.
The present work was specially designed to
respect the normal conditions of daily activity. The
differences in the observed findings between this
and previous studies'5"71 could be due in part to
the differences in the study protocol. For instance,
in Cryer's study"1 the subjects were in the supine
position for 30 min before and throughout smok-
ing, while our subjects were not. This could explain
higher catecholamine mean values before smoking
in our total population and the absence of cate-
cholamine increase (mean values) 20 min following
smoking.
Finally, the haemodynamic changes observed in
our study in the absence of catecholamine increase
could be related to substances other than nico-
tine, inhaled during smoking and acting on the
cardiovascular system, as suggested by recent
publications127 ~291.
Smoking-induced potentiation of platelet aggre-
gation is another mechanism proposed to explain
the increased incidence of ischaemic accidents in
cigarette smokers'5'. Using sensitive methods for
the in vivo detection of platelet activation, we can-
not confirm this hypothesis in our population at 20
min following the beginning of smoking. These
results are in accordance with a recent work in
which blood was sampled in coronary sinus and
studied with same methods'301. However, our
results do not exclude slight platelet modifications
as previously demonstrated by in vitro provocative
test141.
Finally, oxytocin-associated-neurophysin is
found to be extremely high in the 4 females who
were taking oral contraceptives, and was not
related to smoking. We have previously shown, in
a larger population, high values of ESN in women
on oral contraceptives, during pregnancy and in
men undergoing diethylstilbestrol therapy for pros-
tate carcinoma'171. Such high ESN levels probably
reflect very high levels of oxytocin which can pro-
mote cardiac accidents in predisposed subjects'3'1.
Although the vasoactive properties'321 of oxytocin
are not well defined (particularly in women during-
chronic use), this finding could bring a new light on
the fact that oral contraception increases the risk
of cardiovascular morbidity and mortality1331.
Further and larger studies are necessary to confirm
this hypothesis.
In conclusion, it was recently demonstrated that
cessation of smoking after myocardial infarction is
associated with a considerably higher survival rate
and lower cumulative frequency of reinfarction'121.
The present study suggests that this beneficial
effect could be the result of improvement of a
factor such as vasopressin secretion rather than
platelet activation or catecholamines release.
The authors thank Ms M. Turrian for secretarial
assistance.
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